Cargando…
Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
The association between natalizumab and progressive multifocal leukoencephalopathy (PML) is established, but a reliable clinical risk stratification flow-chart is lacking. New risk factors are needed, such as the possible role of the anti-JC polyomavirus (JCPyV) neutralizing antibody. In this pilot...
Autores principales: | Diotti, Roberta Antonia, Capra, Ruggero, Moiola, Lucia, Caputo, Valeria, De Rossi, Nicola, Sangalli, Francesca, Martinelli, Vittorio, Burioni, Roberto, Clementi, Massimo, Mancini, Nicasio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885083/ https://www.ncbi.nlm.nih.gov/pubmed/27164128 http://dx.doi.org/10.3390/v8050128 |
Ejemplares similares
-
JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients
por: Agostini, Simone, et al.
Publicado: (2021) -
Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab
por: Mancuso, Roberta, et al.
Publicado: (2022) -
Human Polyomavirus JCPyV and Its Role in Progressive Multifocal Leukoencephalopathy and Oncogenesis
por: Del Valle, Luis, et al.
Publicado: (2019) -
JCPyV-Induced MAPK Signaling Activates Transcription Factors during Infection
por: DuShane, Jeanne K., et al.
Publicado: (2019) -
Discriminating between JCPyV and BKPyV in Urinary Virome Data Sets
por: Mormando, Rita, et al.
Publicado: (2021)